Bellerophon Therapeutics, Inc. News Releases http://investors.bellerophon.com/ Bellerophon Therapeutics, Inc. News Releases en Bellerophon to Present at the JMP Securities Life Sciences Conference http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-present-jmp-securities-life-sciences-conference WARREN, N.J. , June 13, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, announced today that Fabian Tenenbaum , Chief Executive Officer, will present a corporate overview at the JMP Securities Life Thu, 13 Jun 2019 08:00:00 -0400 Bellerophon Therapeutics, Inc. News Releases 8906 Bellerophon to Host Key Opinion Leader Meeting Focused on Pulmonary Hypertension Associated with Interstitial Lung Disease http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-host-key-opinion-leader-meeting-focused-pulmonary WARREN, N.J. , May 22, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it will host a Key Opinion Leader (KOL) lunch meeting focused on Pulmonary Hypertension Associated with Wed, 22 May 2019 08:30:00 -0400 Bellerophon Therapeutics, Inc. News Releases 8856 Bellerophon Presents Additional Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at American Thoracic Society 115th International Conference http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-presents-additional-positive-data-cohort-1-ongoing Results Presented in Late-Breaking Abstract as an Oral Presentation WARREN, N.J. , May 21, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, presented additional data from Cohort 1 of its ongoing Phase Tue, 21 May 2019 08:30:00 -0400 Bellerophon Therapeutics, Inc. News Releases 8846 Bellerophon to Present Additional Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at American Thoracic Society 115th International Conference http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-present-additional-data-cohort-1-ongoing-phase-23 Results to be Presented in Late-Breaking Abstract as an Oral Presentation Company will Also Present a Corporate Overview and Update on its PH-ILD Program at Respiratory Innovation Summit WARREN, N.J. , May 13, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. Mon, 13 May 2019 08:30:00 -0400 Bellerophon Therapeutics, Inc. News Releases 8826 Bellerophon Provides Business Update and Reports First Quarter 2019 Financial Results http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-provides-business-update-and-reports-first-quarter-1 WARREN, N.J. , May 09, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the first quarter ended March 31, 2019 . Thu, 09 May 2019 08:30:00 -0400 Bellerophon Therapeutics, Inc. News Releases 8811 Bellerophon Announces Agreement with FDA on Regulatory Approval Pathway for INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-announces-agreement-fda-regulatory-approval-pathway FDA Agrees to Primary Endpoint of Change in Moderate to Vigorous Physical Activity from Baseline to Week 16, Measured by Actigraphy FDA Also Agrees on Modification of Ongoing Phase 2b Study into a Phase 2/3 Trial, with Cohort 3 Serving as the Pivotal Phase 3 Study Completion of Cohort 2 and Mon, 08 Apr 2019 08:30:00 -0400 Bellerophon Therapeutics, Inc. News Releases 8796 Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2018 Financial Results http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-provides-business-update-and-reports-fourth-0 WARREN, N.J. , March 14, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2018 . Thu, 14 Mar 2019 08:30:00 -0400 Bellerophon Therapeutics, Inc. News Releases 8756 Bellerophon to Present Clinical Data Supporting Actigraphy as a Clinically Meaningful Endpoint to Detect Improvements in Pulmonary Fibrosis Patients   http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-present-clinical-data-supporting-actigraphy Actigraphy is Being Utilized to Evaluate Multiple Clinically Meaningful Activity Parameters in the Ongoing INOpulse® Phase 2b Clinical Trial for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease Data to be Presented in a Poster Session at the 13 th Annual Pulmonary Mon, 28 Jan 2019 08:31:11 -0500 Bellerophon Therapeutics, Inc. News Releases 8631 Bellerophon Announces Closing of $7 Million Public Offering of Common Stock http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-announces-closing-7-million-public-offering-common WARREN, N.J. , Jan. 25, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the closing and funding of its previously announced underwritten public offering of 10,000,000 shares of its Fri, 25 Jan 2019 16:05:53 -0500 Bellerophon Therapeutics, Inc. News Releases 8626 Bellerophon Announces Pricing of $7 Million Public Offering of Common Stock http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-announces-pricing-7-million-public-offering-common WARREN, N.J. , Jan. 23, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering Wed, 23 Jan 2019 06:00:31 -0500 Bellerophon Therapeutics, Inc. News Releases 8621